| Identification | Back Directory | [Name]
4H-Pyrazolo[4,3-c]quinolin-4-one, 1,5-dihydro-7-(2-methoxy-3,5-dimethyl-4-pyridinyl)-1-[(3S)-tetrahydro-3-furanyl]- | [CAS]
1429509-82-9 | [Synonyms]
E2027
Irsenontrine
Irsenontrine (Synonyms: E2027)
4H-Pyrazolo[4,3-c]quinolin-4-one, 1,5-dihydro-7-(2-methoxy-3,5-dimethyl-4-pyridinyl)-1-[(3S)-tetrahydro-3-furanyl]- | [Molecular Formula]
C22H22N4O3 | [MOL File]
1429509-82-9.mol | [Molecular Weight]
390.44 |
| Chemical Properties | Back Directory | [Boiling point ]
514.6±50.0 °C(Predicted) | [density ]
1.41±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, away from moisture and light | [form ]
Solid | [pka]
12.41±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases[1][2][3]. | [in vivo]
Irsenontrine (0.3, 3.3 mg/kg; p.o.) exhibits a significant ameliorative effect on the percentage of exploration of the novel object at 3.3 mg/kg in Scopolamine-induced rats[1].
Irsenontrine (1 mg/kg; p.o.) and memantine hydrochloride (1 mg/kg; p.o.) combined treatment group exhibits a significantly higher percentage of exploration of the novel object than memantine hydrochloride (1 mg/kg) alone[1]. | [storage]
4°C, away from moisture and light | [References]
[1] Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1
[2] Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36(4):309-319. DOI:10.1007/s40266-018-00636-7
[3] Eisai to present latest research on Alzheimer’s disease / dementia pipeline at the 14th international conference on Alzheimer’s & Parkinson’s diseases |
|
|